Medpace (NASDAQ:MEDP) Given New $362.00 Price Target at Robert W. Baird

Medpace (NASDAQ:MEDP) had its price objective boosted by Robert W. Baird from $354.00 to $362.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Robert W. Baird’s price target points to a potential upside of 3.22% from the company’s current price.

Several other research analysts also recently weighed in on MEDP. Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Truist Financial dropped their target price on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Redburn Atlantic assumed coverage on Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 target price for the company. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Finally, TD Cowen cut their price target on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Trading Up 1.9 %

MEDP stock traded up $6.63 during mid-day trading on Monday, hitting $350.70. The stock had a trading volume of 49,948 shares, compared to its average volume of 207,450. Medpace has a 52 week low of $286.76 and a 52 week high of $459.77. The firm has a market capitalization of $10.90 billion, a P/E ratio of 30.69, a P/E/G ratio of 1.77 and a beta of 1.36. The firm has a fifty day simple moving average of $340.33 and a 200 day simple moving average of $354.73.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. R Squared Ltd acquired a new stake in Medpace in the fourth quarter valued at $30,000. Stone House Investment Management LLC acquired a new stake in shares of Medpace during the 3rd quarter worth about $33,000. Ashton Thomas Securities LLC acquired a new position in Medpace in the third quarter valued at approximately $37,000. Capital Performance Advisors LLP acquired a new position in shares of Medpace in the 3rd quarter valued at $46,000. Finally, True Wealth Design LLC grew its position in shares of Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after buying an additional 168 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.